JP7438662B2 - Ｔ細胞依存性二重特異的抗体をアッセイするための方法 - Google Patents

Ｔ細胞依存性二重特異的抗体をアッセイするための方法 Download PDF

Info

Publication number
JP7438662B2
JP7438662B2 JP2018538107A JP2018538107A JP7438662B2 JP 7438662 B2 JP7438662 B2 JP 7438662B2 JP 2018538107 A JP2018538107 A JP 2018538107A JP 2018538107 A JP2018538107 A JP 2018538107A JP 7438662 B2 JP7438662 B2 JP 7438662B2
Authority
JP
Japan
Prior art keywords
cells
cell
target
tdb
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018538107A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504321A5 (enExample
JP2019504321A (ja
Inventor
ホヨン リー，
クオイン チアン，
ピン イー ウォン，
ケンドール キャリー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2019504321A publication Critical patent/JP2019504321A/ja
Publication of JP2019504321A5 publication Critical patent/JP2019504321A5/ja
Priority to JP2021155968A priority Critical patent/JP2022023062A/ja
Priority to JP2023097744A priority patent/JP2023138948A/ja
Application granted granted Critical
Publication of JP7438662B2 publication Critical patent/JP7438662B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02006—Beta-lactamase (3.5.2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
JP2018538107A 2016-01-25 2017-01-25 Ｔ細胞依存性二重特異的抗体をアッセイするための方法 Active JP7438662B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021155968A JP2022023062A (ja) 2016-01-25 2021-09-24 Ｔ細胞依存性二重特異的抗体をアッセイするための方法
JP2023097744A JP2023138948A (ja) 2016-01-25 2023-06-14 Ｔ細胞依存性二重特異的抗体をアッセイするための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662286862P 2016-01-25 2016-01-25
US62/286,862 2016-01-25
PCT/US2017/014974 WO2017132279A1 (en) 2016-01-25 2017-01-25 Methods for assaying t-cell dependent bispecific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021155968A Division JP2022023062A (ja) 2016-01-25 2021-09-24 Ｔ細胞依存性二重特異的抗体をアッセイするための方法

Publications (3)

Publication Number Publication Date
JP2019504321A JP2019504321A (ja) 2019-02-14
JP2019504321A5 JP2019504321A5 (enExample) 2020-03-05
JP7438662B2 true JP7438662B2 (ja) 2024-02-27

Family

ID=57966203

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018538107A Active JP7438662B2 (ja) 2016-01-25 2017-01-25 Ｔ細胞依存性二重特異的抗体をアッセイするための方法
JP2021155968A Withdrawn JP2022023062A (ja) 2016-01-25 2021-09-24 Ｔ細胞依存性二重特異的抗体をアッセイするための方法
JP2023097744A Pending JP2023138948A (ja) 2016-01-25 2023-06-14 Ｔ細胞依存性二重特異的抗体をアッセイするための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021155968A Withdrawn JP2022023062A (ja) 2016-01-25 2021-09-24 Ｔ細胞依存性二重特異的抗体をアッセイするための方法
JP2023097744A Pending JP2023138948A (ja) 2016-01-25 2023-06-14 Ｔ細胞依存性二重特異的抗体をアッセイするための方法

Country Status (5)

Country Link
US (2) US11513127B2 (enExample)
EP (1) EP3408671B1 (enExample)
JP (3) JP7438662B2 (enExample)
CN (2) CN109073635A (enExample)
WO (1) WO2017132279A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL263466B2 (en) 2013-12-17 2023-10-01 Genentech Inc Anti-CD3 antibodies and methods of using them
MA40579A (fr) 2014-09-12 2016-03-17 Genentech Inc Anticorps anti-cll-1 et immunoconjugués
HRP20201779T1 (hr) 2015-05-28 2021-01-22 Genentech, Inc. Stanični test za otkrivanje anti-cd3 homodimera
DK3310814T5 (da) 2015-06-16 2024-10-07 Hoffmann La Roche Humaniserede og affinitetsmodnede antistoffer mod FcRH5 og fremgangsmåder til anvendelse
US10501545B2 (en) 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
JP7784795B2 (ja) 2016-11-15 2025-12-12 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
BR112020013910A2 (pt) * 2018-01-08 2020-12-01 H. Lee Moffitt Cancer Center And Research Institute Inc. composições e métodos para alvejamento de cânceres que expressam cd99
CN111699200B (zh) 2018-01-15 2023-05-26 南京传奇生物科技有限公司 针对pd-1的单域抗体和其变体
IL325995A (en) 2018-02-08 2026-03-01 Genentech Inc Bispecific antigen binding molecules and methods of use
CN108918892B (zh) * 2018-08-01 2021-04-27 百奥泰生物制药股份有限公司 一种测定抗vegf抗体活性的方法及其应用
CN110872356B (zh) * 2018-09-03 2023-06-13 广西慧宝源健康产业有限公司 双特异性抗体及其使用方法
EP3850013A4 (en) 2018-09-10 2022-10-05 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AGAINST CLL1 AND USES THEREOF
TW202028244A (zh) * 2018-10-09 2020-08-01 美商建南德克公司 用於確定突觸形成之方法及系統
CN109402168A (zh) * 2018-10-30 2019-03-01 深圳新诺微环生物科技有限公司 微环dna表达连接her2阳性细胞与效应细胞的桥接分子及其应用
CN112798786B (zh) * 2019-11-14 2022-04-29 深圳先进技术研究院 一种基于荧光素酶互补的生物传感器及其制备方法和应用
WO2021119505A1 (en) 2019-12-13 2021-06-17 Genentech, Inc. Anti-ly6g6d antibodies and methods of use
AU2021239929A1 (en) * 2020-03-16 2022-10-13 Crispr Therapeutics Ag T-cell bispecific binding proteins
WO2022067005A1 (en) * 2020-09-27 2022-03-31 Genentech, Inc. High throughput multiparametric immune cell engager screening assay
AU2021374594B2 (en) 2020-11-04 2026-03-05 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
JP7716473B2 (ja) 2020-11-04 2025-07-31 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
TWI874719B (zh) 2020-11-04 2025-03-01 美商建南德克公司 用抗cd20/抗cd3雙特異性抗體進行治療之給藥
CN112458149B (zh) * 2020-12-03 2021-10-08 北京东方百泰生物科技股份有限公司 一种以cd3为靶点的抗体药物对t细胞激活程度的检测方法
EP4337330A1 (en) 2021-05-14 2024-03-20 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
WO2023250485A1 (en) 2022-06-23 2023-12-28 LAVA Therapeutics N.V. Assay for t cell dependent multispecific compounds
EP4573125A1 (en) * 2022-08-18 2025-06-25 Immunocore Limited Multi-domain binding molecules
CN120077068A (zh) * 2022-08-18 2025-05-30 英美偌科有限公司 多结构域结合分子

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508163A (ja) 2002-11-27 2006-03-09 アジェンシス， インコーポレイテッド 癌の処置および検出において有用な２４ｐ４ｃ１２と称される、核酸および対応タンパク質
US20150203579A1 (en) 2014-01-23 2015-07-23 Regeneron Pharmaceuticals, Inc. Human Antibodies to PD-1
WO2015142314A1 (en) 2013-03-15 2015-09-24 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3850542T2 (de) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO1992000373A1 (en) 1990-06-29 1992-01-09 Biosource Genetics Corporation Melanin production by transformed microorganisms
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
WO1993016177A1 (en) 1992-02-11 1993-08-19 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
AU2814897A (en) * 1996-04-25 1997-11-12 T Cell Sciences, Inc. Method of isolating regulators of t cell activation
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US8372954B2 (en) 2000-12-22 2013-02-12 National Research Council Of Canada Phage display libraries of human VH fragments
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
AU2005285347A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
WO2010129304A2 (en) * 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2013026839A1 (en) * 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2769989A1 (en) * 2013-02-21 2014-08-27 Universitätsklinikum Freiburg Recombinant bispecific antibody that binds to the CD133 antigen on tumor cells and to the human CD3 T cell receptor
ES2905615T3 (es) * 2014-11-20 2022-04-11 Promega Corp Sistemas y métodos para evaluar moduladores de puntos de control inmunitario
HRP20201779T1 (hr) 2015-05-28 2021-01-22 Genentech, Inc. Stanični test za otkrivanje anti-cd3 homodimera
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
WO2018108759A1 (en) * 2016-12-13 2018-06-21 F. Hoffmann-La Roche Ag Method to determine the presence of a target antigen in a tumor sample

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508163A (ja) 2002-11-27 2006-03-09 アジェンシス， インコーポレイテッド 癌の処置および検出において有用な２４ｐ４ｃ１２と称される、核酸および対応タンパク質
WO2015142314A1 (en) 2013-03-15 2015-09-24 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
US20150203579A1 (en) 2014-01-23 2015-07-23 Regeneron Pharmaceuticals, Inc. Human Antibodies to PD-1

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ＤＯＮＧＨＡＩ ＷＡＮＧ ｅｔ ａｌ．，"ＣＤ３／ＣＤ２８ Ｃｏｓｔｉｍｕｌａｔｉｏｎ－Ｉｎｄｕｃｅｄ ＮＦ－κＢ Ａｃｔｉｖａｔｉｏｎ Ｉｓ Ｍｅｄｉａｔｅｄ ｂｙ Ｒｅｃｒｕｉｔｍｅｎｔ ｏｆ Ｐｒｏｔｅｉｎ Ｋｉｎａｓｅ Ｃ－θ， Ｂｃｌ１０， ａｎｄ ＩκＢ Ｋｉｎａｓｅ β ｔｏ ｔｈｅ Ｉｍｍｕｎｏｌｏｇｉｃａｌ Ｓｙｎａｐｓｅ ｔｈｒｏｕｇｈ ＣＡＲＭＡ１"， ＭＯＬＥＣＵＬＡＲ ＡＮＤ ＣＥＬＬＵＬＡＲ ＢＩＯＬＯＧＹ， ２００４年１月， Ｖｏｌ．２４， Ｎｏ．１，ｐ．１６４－１７１，ＵＲＬ， ｈｔｔｐｓ：／／ｗｗｗ．ｒｅｓｅａｒｃｈｇａｔｅ．ｎｅｔ／ｐｕｂｌｉｃａｔｉｏｎ／８９６１７９０＿ＣＤ３ＣＤ２８＿Ｃｏｓｔｉｍｕｌａｔｉｏｎ－Ｉｎｄｕｃｅｄ＿ＮＦ－ｋＢ＿Ａｃｔｉｖａｔｉｏｎ＿Ｉｓ＿Ｍｅｄｉａｔｅｄ＿ｂｙ＿Ｒｅｃｒｕｉｔｍｅｎｔ＿ｏｆ＿Ｐｒｏｔｅｉｎ＿Ｋｉｎａｓｅ＿Ｃ－ｔｈ＿Ｂｃｌ１０＿ａｎｄ＿ＩｋＢ＿Ｋｉｎａｓｅ＿ｂ＿ｔｏ＿ｔｈｅ＿Ｉｍｍｕｎｏｌｏｇｉｃａｌ＿Ｓｙｎａｐｓｅ＿ｔｈｒｏｕｇｈ＿ＣＡＲＭＡ１
ＰＥＴＥ ＳＴＥＣＨＡ ｅｔ ａｌ．，"Ｄｅｖｅｌｏｐｍｅｎｔ ｏｆ ａ ｒｏｂｕｓｔ ｒｅｐｏｒｔｅｒ－ｂａｓｅｄ Ｔ－ｃｅｌｌ ａｃｔｉｖａｔｉｏｎ ａｓｓａｙ ｆｏｒ ｂｉｓｐｅｃｉｆｉｃ ｔｈｅｒａｐｅｕｔｉｃ ａｎｔｉｂｏｄｉｅｓ ｉｎ ｉｍｍｕｎｏｔｈｅｒａｐｙ"，ＣＡＮＣＥＲ ＲＥＳＥＡＲＣＨ，２０１５年８月１日，Ｖｏｌｕｍｅ７５，Ｉｓｓｕｅ１５ Ｓｕｐｐｌｅｍｅｎｔ，Ａｂｓｔｒａｃｔ ５４３９，ｐ．１－４，ＵＲＬ，ｈｔｔｐｓ：／／ａａｃｒｊｏｕｒｎａｌｓ．ｏｒｇ／ｃａｎｃｅｒｒｅｓ／ａｒｔｉｃｌｅ／７５／１５＿Ｓｕｐｐｌｅｍｅｎｔ／５４３９／６０４６５１／Ａｂｓｔｒａｃｔ－５４３９－Ｄｅｖｅｌｏｐｍｅｎｔ－ｏｆ－ａ－ｒｏｂｕｓｔ－ｒｅｐｏｒｔｅｒ
ＺＨＩ－ＪＩＥ ＣＨＥＮＧ ＪＥＹ ｅｔ ａｌ．，"Ｄｅｖｅｌｏｐｍｅｎｔ ｏｆ ａ Ｒｏｂｕｓｔ Ｒｅｐｏｒｔｅｒ－ｂａｓｅｄ Ｔ ｃｅｌｌ Ａｃｔｉｖａｔｉｏｎ Ａｓｓａｙ ｆｏｒ Ｔｈｅｒａｐｅｕｔｉｃ Ｂｉｏｌｏｇｉｃｓ ｉｎ Ｉｍｍｕｎｏｔｈｅｒａｐｙ"，［ＯＮＬＩＮＥ］，２０１４年５月２日，ｐ．１，ＵＲＬ，ｈｔｔｐｓ：／／ｃｄｎ．ｔｅｃｈｎｏｌｏｇｙｎｅｔｗｏｒｋｓ．ｃｏｍ／ＴＮ／Ｒｅｓｏｕｒｃｅｓ／ＰＤＦ／ｄｅｖｅｌｏｐｍｅｎｔ－ｏｆ－ａ－ｒｏｂｕｓｔ－ｒｅｐｏｒｔｅｒ－ｂａｓｅｄ－ｔ－ｃｅｌｌ－ａｃｔｉｖａｔｉｏｎ－ａｓｓａｙ－ｆｏｒ－ｔｈｅｒａｐｅｕｔｉｃ－ｂｉｏｌｏｇｉｃｓ－ｉｎ．ｐｄｆ

Also Published As

Publication number Publication date
JP2022023062A (ja) 2022-02-07
EP3408671A1 (en) 2018-12-05
US11513127B2 (en) 2022-11-29
JP2023138948A (ja) 2023-10-03
US20200182882A1 (en) 2020-06-11
US20230280355A1 (en) 2023-09-07
CN121364307A (zh) 2026-01-20
EP3408671B1 (en) 2023-11-01
WO2017132279A1 (en) 2017-08-03
EP3408671C0 (en) 2023-11-01
CN109073635A (zh) 2018-12-21
JP2019504321A (ja) 2019-02-14
WO2017132279A8 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
JP7438662B2 (ja) Ｔ細胞依存性二重特異的抗体をアッセイするための方法
US20240280586A1 (en) CELL-BASED ASSAY FOR DETECTING ANTl-CD3 HOMODIMERS
JP2015537212A (ja) イオン強度媒介のｐｈ勾配イオン交換クロマトグラフィー
EP3729080B1 (en) Universal reporter cell assay for specificity test of novel antigen binding moieties
JP2019530857A (ja) 非イオン性サーファクタント及びポリペプチドを含む組成物中の非イオン性サーファクタントを定量するためのクロマトグラフィー法
US20220137067A1 (en) Antibody potency assay
KR102251127B1 (ko) 이온 교환 크로마토그래피 입력 최적화의 설명
SG187787A1 (en) Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
HK40130187A (zh) 用於测定t细胞依赖性双特异性抗体的方法
HK40002064A (en) Methods for assaying t-cell dependent bispecific antibodies
HK1250045B (zh) 用於檢測抗cd3同二聚體的基於細胞的測定
BR112017025051B1 (pt) Métodos para detecção e para quantificar a quantidade de homodímeros anti-cd3 em uma composição compreendendo um anticorpo biespecífico dependente de células t (tdb) e kit para a detecção de homodímeros anti-cd3 em uma composição

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210510

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210525

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210924

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20211102

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220412

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221011

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221114

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20230221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230821

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240214

R150 Certificate of patent or registration of utility model

Ref document number: 7438662

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150